Browse the evidence

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

GLP-1RA prescriptions significantly increased across all BMI categories among youth and adults with type 1 diabetes over the last 15 years.

Clinicians should consider the increasing use of GLP-1RAs in managing obesity in T1D patients.

Advancements in laparoscopic surgical technique have improved the safety and efficacy of bariatric metabolic surgery.

Surgeons should adopt new laparoscopic techniques to enhance patient outcomes in bariatric surgery.

Patients who received the fluid-filled IGB were more likely to require urgent evaluation or treatment compared to those treated with the gas-filled IGB.

Clinicians should be aware of the higher likelihood of complications with the fluid-filled IGB.

Recent insights into pathophysiological mechanisms suggest that OSA may be divided into distinct subgroups.

Understanding the subgroups in OSA may lead to more targeted treatments.

Recent drug candidates show a convincing reduction of sleep disordered breathing in both short and intermediate term.

New drug candidates may offer effective treatment options for OSA patients.

GLP-1RAs may have little or no effect on breast cancer risk.

Practitioners should consider that GLP-1RAs may not significantly increase breast cancer risk based on current evidence.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

The time of day does not significantly moderate the association between MVPA and all-cause mortality.

Patients can perform MVPA at any time of day without concern for timing affecting mortality.

Substituting evening MVPA with morning MVPA does not lead to appreciable changes in all-cause mortality.

The timing of MVPA (morning vs evening) is not critical for mortality outcomes.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.

Practitioners should be aware of the limitations of current oral obesity treatments.

A dual/poly-GPCR agonism strategy has emerged as an alternative approach to the traditional mono-GPCR concept.

Practitioners may consider exploring dual/poly-GPCR strategies in obesity treatment.

The mechanism-based therapeutic potential and limitations of oral poly-GPCR agonism strategy to augment intestinal GLP-1 for weight loss are projected.

Practitioners should evaluate the potential of oral poly-GPCR agonism in enhancing GLP-1 for weight loss.

Total weight loss was not different between exercising and nonexercising subjects.

Weight loss outcomes may not differ significantly between those who exercise and those who do not when on a restricted diet.

Resting metabolic rate (RMR) declined similarly in both exercising and nonexercising groups.

Both exercising and nonexercising individuals may experience similar declines in metabolic rate during caloric restriction.

The plant-based, low-fat diet resulted in substantially greater glucose and insulin levels.

Practitioners should be aware that a plant-based, low-fat diet may increase glucose and insulin levels.

There is a general trend showing higher mortality in patients with the greatest weight loss (weight reduction >10 kg).

Practitioners should be cautious about promoting excessive weight loss in this population.

Low fat intake is associated with a higher risk of all-cause dementia (HR 1.42 (95%CI: 1.11-1.82)).

Practitioners should be cautious about recommending very low fat diets for older adults due to potential dementia risk.

No leucine metabolite attenuated inflammation during training.

Leucine metabolites should not be recommended for reducing inflammation in resistance training.

Food overproduction contributes to an environment that encourages overconsumption.

Strategies to manage food production should consider its impact on consumption patterns.

Governments need to implement policies to address the food environment to reverse obesity.

Policymakers should focus on comprehensive strategies to improve the food environment.

Many popular diets remain untested by prospective randomized trials, raising concerns about their long-term health effects.

Caution is advised when recommending popular diets due to lack of evidence.

The FDA requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function.

Health professionals should be aware of the regulatory warnings associated with olestra.